The Journal of Practical Medicine >
Effect of omalizumab injection combined with compound glycyrrhizin tablets on chronic urticaria with low response to antihistamines
Received date: 2024-12-06
Online published: 2025-04-30
Objective To investigate the effectiveness and safety of combining Omalizumab with compound glycyrrhetinic acid glycoside in the management of chronic urticaria that exhibits poor response to antihistamine therapy. Methods 92 patients with chronic urticaria who were treated with H1 antihistamines and still had symptoms from February 2022 to February 2024 in the hospital were selected as the study subjects. The study participants were randomly assigned to either the observation group， consisting of 46 cases， or the control group， also comprising 46 cases， using a random number table method. The control group received subcutaneous injection of omalizumab for treatment. The observation group was treated with oral compound glycyrrhizin tablets on the basis of the control group. After 24 weeks of treatment， compare the efficacy， adverse reactions， Urticaria Activity Score over 7 days （UAS7）， Dermatology Life Quality Index （DLQI）， Immunoglobulin （Ig） E， and High Sensitivity C-reactive protein （hs CRP） between the two groups， and record the recurrence rate. Results After treatment， the UAS7， DLQI， IgE and hs-CRP of both groups of patients decreased compared to before treatment， and the observation group demonstrated lower results compared to the control group （P < 0.05）. After treatment， the overall effectiveness rate in the observation group exceeded that of the control group（P < 0.05）， and the recurrence rate was lower than that of the control group （P < 0.05）. There was no statistically significant difference in the incidence of adverse reactions between the two groups of drugs （P > 0.05）. Conclusion The combination therapy of omalizumab and compound glycyrrhetinic acid glycoside in the treatment of chronic urticaria patients with low response to antihistamines helps reduce IgE expression， improve treatment effectiveness， lower recurrence rates， and does not increase adverse drug reactions.
Haixia SHI , Yuan GUO , Yanhua LI , Juping CHEN , Haochen YUAN , Yun. ZHANG . Effect of omalizumab injection combined with compound glycyrrhizin tablets on chronic urticaria with low response to antihistamines[J]. The Journal of Practical Medicine, 2025 , 41(8) : 1212 -1216 . DOI: 10.3969/j.issn.1006-5725.2025.08.018
| 1 | KOLKHIR P， MUNOZ M， ASERO R， et al. Autoimmune chronic spontaneous urticaria［J］. J Allergy Clin Immunol，2022，149（6）：1819-1831. doi:10.1016/j.jaci.2022.04.010 |
| 2 | MAURER M， BERGER W， GIMENEZ-ARNAU A， et al. Remibrutinib， a novel BTK inhibitor， demonstrates promising efficacy and safety in chronic spontaneous urticaria［J］. J Allergy Clin Immunol，2022，150（6）：1498-1506. doi:10.1016/j.jaci.2022.08.027 |
| 3 | 刘薇. 地氯雷他定治疗过敏性疾病的临床研究进展［J］. 中国临床药理学与治疗学，2010，15 （7）：821-826. |
| 4 | CASALE T B， GIMENEZ-ARNAU A M， BERNSTEIN J A， et al. Omalizumab for Patients with Chronic Spontaneous Urticaria： A Narrative Review of Current Status［J］. Dermatol Ther （Heidelb），2023，13（11）：2573-2588. doi:10.1007/s13555-023-01040-9 |
| 5 | KOLKHIR P， GIMENEZ-ARNAU A M， KULTHANAN K， et al. Urticaria［J］. Nat Rev Dis Primers，2022，8（1）：61. doi:10.1038/s41572-022-00389-z |
| 6 | KAPLAN A， LEBWOHL M， GIMENEZ-ARNAU A M， et al. Chronic spontaneous urticaria： Focus on pathophysiology to unlock treatment advances［J］. Allergy，2023，78（2）：389-401. doi:10.1111/all.15603 |
| 7 | LACAVA A F， FADUGBA O O. Cyclosporine for omalizumab-refractory chronic urticaria： A report of five cases［J］. Allergy Asthma Clin Immunol，2023，19（1）：78. doi:10.1186/s13223-023-00820-4 |
| 8 | ZUBERBIER T， ABDUL L A， ABUZAKOUK M， et al. The international EAACI/GA（2）LEN/EuroGuiDerm/APAAACI guideline for the definition， classification， diagnosis， and management of urticaria［J］. Allergy，2022，77（3）：734-766. |
| 9 | CHEN S， CAO W， XIAO X， et al. A systematic review and meta-analysis of efficacy and safety of compound glycyrrhizin combined with second-generation non-sedated antihistamine for the treatment of chronic urticaria［J］. J Dermatolog Treat，2024，35（1）：2299597. doi:10.1080/09546634.2023.2299597 |
| 10 | ORZAN O A， POPA L G， MIHAI M M， et al. Current and future approaches in management of chronic spontaneous urticaria using anti-IgE antibodies［J］. Medicina （Kaunas），2022，58（6）：816. doi:10.3390/medicina58060816 |
| 11 | 沈钰，蒋博宣，谢勇，等. 中药三黄苦参洗剂联合自制抗敏止痒乳膏治疗女性外阴慢性湿疹的效果观察［J］. 南通大学学报（医学版），2020，40（2）：188-190. |
| 12 | 李思彤，王傲，白彦萍，等. 银屑病中滤泡性辅助性T细胞及IL-21对HaCaT细胞增殖及细胞周期的影响［J］. 实用医学杂志，2023，39（18）：2342-2348. doi:10.3969/j.issn.1006-5725.2023.18.010 |
| 13 | ZUBERBIER T， PETER J， STAUBACH P， et al. Potential Therapeutic Approaches for Chronic Urticaria： Beyond H1-Antihistamines and Biologics［J］. J Allergy Clin Immunol Pract，2023，11（8）：2265-2273. doi:10.1016/j.jaip.2023.06.027 |
| 14 | NOCHAIWONG S， CHUAMANOCHAN M， RUENGORN C， et al. Impact of pharmacological treatments for chronic spontaneous urticaria with an inadequate response to H1-antihistamines on health-related quality of life： A systematic review and network meta-analysis［J］. J Allergy Clin Immunol Pract，2022，10（1）：297-308. doi:10.1016/j.jaip.2021.10.022 |
| 15 | KEUMALA B W， MAHRI S， ALMIRA D. The Role of Adjuvant Therapy in the Management of Chronic Urticaria［J］. Actas Dermosifiliogr，2023，114（6）：T523-T530. doi:10.1016/j.ad.2023.02.015 |
| 16 | TURK M， ERTAS R， SAHINER U M， et al. In Chronic Spontaneous Urticaria， Complete Response to Antihistamine Treatment Is Linked to Low Disease Activity［J］. Int Arch Allergy Immunol，2023，184（5）：421-432. doi:10.1159/000528395 |
| 17 | 中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2022版）［J］. 中华皮肤科杂志，2022，55（12）：1041-1049. |
| 18 | 岳淑珍，树叶，罗鸯鸯，等. 奥马珠单抗治疗儿童慢性荨麻疹的疗效和安全性回顾研究［J］. 中华皮肤科杂志，2024，57（4）：354-358. |
| 19 | JANG J H， YANG E M， LEE Y， et al. Increased serum free IgE levels in patients with chronic spontaneous urticaria （CSU）［J］. World Allergy Organ J，2022，15（2）：100629. doi:10.1016/j.waojou.2022.100629 |
| 20 | PATRUNO C， GUARNERI F， NETTIS E， et al. Safety of omalizumab in chronic urticaria during pregnancy： A real-life study［J］. Clin Exp Dermatol，2024，49（4）：344-347. doi:10.1093/ced/llad386 |
| 21 | GIMENEZ-ARNAU A M， MANZANARES N， PODDER I. Recent updates in urticaria［J］. Med Clin （Barc），2023，161（10）：435-444. doi:10.1016/j.medcli.2023.06.026 |
| 22 | MAURER M， CASALE T B， SAINI S S， et al. Dupilumab in patients with chronic spontaneous urticaria （LIBERTY-CSU CUPID）： Two randomized， double-blind， placebo-controlled， phase 3 trials［J］. J Allergy Clin Immunol，2024，154（1）：184-194. doi:10.1016/j.jaci.2024.01.028 |
| 23 | BRAS R， COSTA C， LIMAO R， et al. Omalizumab in chronic spontaneous urticaria （CSU）： Real-life experience in dose/interval adjustments and treatment discontinuation［J］. J Allergy Clin Immunol Pract，2023，11（8）：2392-2402. doi:10.1016/j.jaip.2023.01.022 |
| 24 | WEN Y， TANG Y， LI M， et al. Efficiency and safety of desloratadine in combination with compound glycyrrhizin in the treatment of chronic urticaria： A meta-analysis and systematic review of randomised controlled trials［J］. Pharm Biol，2021，59（1）：1276-1285. doi:10.1080/13880209.2021.1973039 |
| 25 | WANG X， YI W， HE L， et al. Abnormalities in Gut Microbiota and Metabolism in Patients With Chronic Spontaneous Urticaria［J］. Front Immunol，2021，12（1）：691304. doi:10.3389/fimmu.2021.691304 |
| 26 | KOLKHIR P， BONNEKOH H， METZ M， et al. Chronic Spontaneous Urticaria： A Review［J］. JAMA，2024，332（17）：1464-1477. doi:10.1001/jama.2024.15568 |
| 27 | PEDERSEN N H， SORENSEN J A， GHAZANFAR M N， et al. Biomarkers for Monitoring Treatment Response of Omalizumab in Patients with Chronic Urticaria［J］. Int J Mol Sci，2023，24（14）：11328. doi:10.3390/ijms241411328 |
| 28 | 种树彬，刘春林. 复方甘草酸苷片联合盐酸西替利嗪治疗慢性荨麻疹患者的临床研究［J］. 中国临床药理学杂志，2022，38（24）：2954-2958. |
/
| 〈 |
|
〉 |